More than 90% of patients with conventionally defined polycythemia vera (PV) are JAK2V617F-positive; the majority of the remaining carry other JAK2 exon 12 mutations. 1 On the basis of PCR sequencing of granulocyte-derived DNA from PV patients, we have previously reported an association between homozygous, as opposed to heterozygous, JAK2V617F mutation pattern and a higher hemoglobin level and increased frequency of pruritus. 2 These findings were recently confirmed by another study that used amplification-refractory mutation sequencing PCR assay 3 to measure JAK2V617F allele burden from granulocyte-derived mRNA in 116 patients with PV (Vannucchi AM et al. Blood 2006; 108: Abstract no. 5); in addition, mutant allele burden in this particular study (median 38%) directly correlated with leukocyte count, spleen size, thrombosis risk and need for treatment. In the current Institutional Review Board-approved study, 103 consecutive patients with PV were selected based on availability of both clinical and laboratory information at diagnosis and archived bone marrow, collected either at the time of diagnosis or during the chronic phase of the disease. All patients fulfilled World Health Organization diagnostic criteria for PV.
Previously published methodology was used for measuring JAK2V617F allele burden in bone marrow-derived DNA. 4 Quantitative PCR amplification and detection were performed on an ABI Prism 7900 HT Analyzer (Applied Biosystems, Foster City, CA, USA). Mutant allele burden was reported as the percentage of total JAK2 represented by JAK2V617F (that is JAK2V617F/JAK2V617F þ JAK2 wild type). 4 This JAK2V617F percentage was obtained from a standard curve for JAK2V617F/ total JAK2 against DC t (Ct JAK2V617F ÀCt JAK2WT ), which was constructed using various proportions of genomic DNA from the cell lines K562 (homozygous for wild-type JAK2) and HEL (homozygous for JAK2V617F). Two microliters of each standard mixture (25 ng/ml) and each sample (25 ng/ml) were aliquoted into separate wells of the 96 well plate. Standards and samples were run in triplicate and the mean DC t , for each standard mixture and sample was used to plot the JAK2V617F/JAK2 total percentage.
Overall, JAK2V617F was detected in 93 patients (90.3%); bone marrow-derived DNA for mutation analysis was collected within 1 year of diagnosis in 57 patients, 1 to 5 years of diagnosis in 20 patients and after 5 years of diagnosis in 16 patients. JAK2V617F allele burden was significantly higher in the latter group compared to the other two groups in whom test samples were collected within 5 years of diagnosis (Table 1 ; P ¼ 0.03). Such time-dependent increase in JAK2V617F allele burden in PV has previously been recognized whereas a similar phenomenon might not occur in essential thrombocythemia (ET); 5 for comparison, we have included, in Table 1 , bone marrow allele burden distributions over time from a previously published study in ET. 6 
Table 1
The effect of time of sample accrual on JAK2V617F allele burden in bone marrow-derived DNA from 93 and 96 mutation-positive patients with polycythemia vera (PV) or essential thrombocythemia (ET), respectively
Time of bone marrow sample collection JAK2V617F allele burden in mutation-positive PV cases (median and range) JAK2V617F allele burden in mutation-positive ET cases 6 (median and range)
At any time during chronic phase of the disease 16% (3-100%) (n ¼ 93) 6.3% (1-100%) (n ¼ 96) Within 1 year of diagnosis 15% (5-100%) (n ¼ 57) 6.5% (2.5-100%) (n ¼ 40) Between 1 and 5 years of diagnosis 14% (3-100%) (n ¼ 20) 5% (1-18%) (n ¼ 31) After 5 years of diagnosis 47% (8-100%) (n ¼ 16) 6.5% (2.5-15%) (n ¼ 25)
JAK2V617F allele burden refers to the proportion of the mutant allele in relation to total JAK2 (that is, JAK2V617F/JAK2V617F + wild-type JAK2).
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Because of the effect of time on allele burden in PV, we restricted clinical correlations to patients in whom JAK2V617F allele burden was performed within 5 years of diagnosis (n ¼ 77, median age at diagnosis 66 years, 43% women). Blood counts at presentation in these 77 patients included medians of 18.6 g/dl for hemoglobin, 439 Â 10 9 /l for platelet count and 11.8 Â 10 9 /l for leukocyte count. At a median follow-up of 38 months, eight deaths, one leukemic transformation and two post-PV myelofibrosis were documented. Arterial and venous thrombosis occurred in 10 (13%) and four (5%) patients at diagnosis and in 15 (19.5%) and four (5%) patients during follow-up, respectively.
Linear regression analysis for continuous variables revealed that JAK2V617F allele burden correlated directly with leukocyte count (Po0.0001) but not with hemoglobin level (P ¼ 0.39), platelet count (P ¼ 0.85), or age (P ¼ 0.85). Similarly, allele burden was not affected by gender (P ¼ 0.9). Allele burden (considered as a continuous variable) was significantly higher in the presence of pruritus (P ¼ 0.003) or microvascular symptoms (P ¼ 0.03) but not palpable splenomegaly (P ¼ 0.89) or cytotoxic therapy during follow-up (n ¼ 57 versus 20 patients not receiving such therapy; P ¼ 0.3). Mutant allele burden was similar between the 14 patients who presented with major thrombosis (both arterial and venous) and the 63 patients who did not (P ¼ 0.32); similarly, allele burden was not significantly different in those patients who developed major thrombosis during follow-up (n ¼ 19) compared to those who did not (n ¼ 58; P ¼ 0.95). The results did not change when arterial thrombosis (P ¼ 0.38 at diagnosis and 0.75 during follow-up) was analyzed separately from venous thrombosis (P ¼ 0.51 at diagnosis and 0.49 during follow-up). The above-mentioned results regarding clinical correlations of bone marrow JAK2V617F allele burden remained the same, for the most part, when allele burden was treated as a categorical variable with either two groups above and below the median value or three groups with allele burdens upto 25% (n ¼ 55), between 25 and 50% (n ¼ 10) and above 50% (n ¼ 12), respectively. The only different outcome was the loss of significant correlation involving microvascular symptoms and pruritus when allele burden was categorized into three groups. Finally, the number of events in terms of death, leukemic transformation, or development of post-PV myelofibrosis was too small to allow valid statistical comparisons of survival or disease transformation.
Taken together, the findings from the current study are underwhelming in terms of clinical relevance of bone marrow JAK2V617F allele burden in PV. The strongest and most consistent correlation was leukocytosis, an observation that warrants the inclusion of leukocyte count as a covariate in any statistical analysis of prognostic relevance that includes JAK2V617F allele burden. This result is pertinent to the recent emphasis on the prognostic relevance of leukocytosis in both PV and ET. 7 Our findings also underline the potential confounding effect of sample accrual time on result interpretation. Finally, we underscore the fact that the current study utilized DNA from archived bone marrow and should not be compared with other studies that have used either DNA 2 Lymphoid neoplasms (LN) are malignancies of lymphocytes, the primary effectors of the immune system. LN are a heterogeneous group including non-Hodgkin's lymphoma (NHL), Hodgkin's lymphoma (HL), multiple myeloma (MM) and chronic lymphocytic leukaemia (CLL) and comprises numerous histological subtypes integrated in the third edition of the WHO International Classification in Oncology since 2001. Altogether, for the year 2000, the annual number of incident cases of LN in France was estimated to be over 17 000 and the number of deaths to almost 9000. The incidence of NHL increased more than 3%
